Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Sell
19
BPTH Quote, Financials, Valuation and Earnings
Last price:
$0.07
Seasonality move
:
23.12%
Day range:
$0.07 - $0.08
52-week range:
$0.05 - $0.23
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
9.98x
Volume:
26.7K
Avg. volume:
21.6K
1-year change:
--
Market cap:
$555.3K
Revenue:
--
EPS (TTM):
-$1.72
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Bio-Path Holdings, Inc. has 2892.31% upside to fair value with a price target of $2.00 per share.
BPTH vs. S&P 500
-
Over the past 5 trading days, Bio-Path Holdings, Inc. has underperformed the S&P 500 by -5.5% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bio-Path Holdings, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bio-Path Holdings, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Bio-Path Holdings, Inc. reported revenues of --.
Earnings Growth
-
Bio-Path Holdings, Inc. has grown year-over-year earnings for 8 quarters straight. In the most recent quarter Bio-Path Holdings, Inc. reported earnings per share of -$0.55.
Enterprise value:
1M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.13x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$153K
Return On Assets:
-413.13%
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$181K | -$166K | -$153K | -$32K | -$41K | |
| Operating Income | -$17.1M | -$13M | -$13.1M | -$3M | -$4.6M | |
| EBITDA | -$16.9M | -$12.9M | -$12.9M | -$3M | -$4.5M | |
| Diluted EPS | -$44.84 | -$17.86 | -$2.14 | -$1.16 | -$0.55 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $30.6M | $20.6M | $6.3M | $5M | $680K | |
| Total Assets | $31.1M | $21M | $6.5M | $5.1M | $746K | |
| Current Liabilities | $1.2M | $1.3M | $1.4M | $3M | $7.9M | |
| Total Liabilities | $1.4M | $1.5M | $1.5M | $3.8M | $7.9M | |
| Total Equity | $29.8M | $19.5M | $5M | $1.3M | -$7.2M | |
| Total Debt | -- | $168K | $55K | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$15.3M | -$8.9M | -$7.9M | -$3.2M | -$283K | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $1.7M | $9.4M | $3.9M | $7M | $161K | |
| Free Cash Flow | -$15.3M | -$8.9M | -$7.9M | -$3.2M | -$283K | |
BPTH
Sector
Market Cap
$555.3K
$28.2M
Price % of 52-Week High
28.86%
50.25%
Dividend Yield
0%
0%
Shareholder Yield
-251.77%
-1.54%
1-Year Price Total Return
-90.21%
-18.1%
Beta (5-Year)
-0.058
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.07
200-day SMA
Sell
Level
$0.13
Bollinger Bands (100)
Sell
Level
0.07 - 0.11
Chaikin Money Flow
Sell
Level
-2.6M
20-day SMA
Sell
Level
$0.07
Relative Strength Index (RSI14)
Sell
Level
43.43
ADX Line
Buy
Level
44.43
Williams %R
Buy
Level
-86.252
50-day SMA
Sell
Level
$0.08
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Sell
Level
-72.9K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Sell
CA Score
(Annual)
Level (-17.5987)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (17.2923)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (0)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
Stock Forecast FAQ
In the current month, BPTH has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BPTH average analyst price target in the past 3 months is $2.00.
-
Where Will Bio-Path Holdings, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bio-Path Holdings, Inc. share price will rise to $2.00 per share over the next 12 months.
-
What Do Analysts Say About Bio-Path Holdings, Inc.?
Analysts are divided on their view about Bio-Path Holdings, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bio-Path Holdings, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Bio-Path Holdings, Inc.'s Price Target?
The price target for Bio-Path Holdings, Inc. over the next 1-year time period is forecast to be $2.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BPTH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bio-Path Holdings, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BPTH?
You can purchase shares of Bio-Path Holdings, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bio-Path Holdings, Inc. shares.
-
What Is The Bio-Path Holdings, Inc. Share Price Today?
Bio-Path Holdings, Inc. was last trading at $0.07 per share. This represents the most recent stock quote for Bio-Path Holdings, Inc.. Yesterday, Bio-Path Holdings, Inc. closed at $0.07 per share.
-
How To Buy Bio-Path Holdings, Inc. Stock Online?
In order to purchase Bio-Path Holdings, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BPTH Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BPTH
Sector
P/E ratio
--
23.92x
PEG ratio
0.00x
-0.01x
P/B ratio
9.98x
1.83x
Price / LTM sales
--
1.61x
Growth Metrics
BPTH
Sector
Revenue growth
--
4.6%
Earnings growth
52.59%
10.88%
Revenue (5-year growth)
--
6.46%
Earnings forecast
-$0.40
-$0.21
Profitability
BPTH
Sector
Profitability FY 2024
-$159K
$3.5M
Return on invested capital
--
-31.84%
Return on assets
-413.13%
-27.96%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Dec
30
Estimated Next Earnings Date
Mar
31
Balance Sheet
BPTH
Sector
Total cash
--
$26.3M
Short term investments
--
$25.7M
Total assets
$3.9M
$76.9M
Long term debt
$479K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 18.81% over the past day.
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Buy
63
GLTO alert for Dec 30
Galecto, Inc. [GLTO] is down 12.13% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
